Edition:
United States

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

4.98EUR
25 May 2017
Change (% chg)

-- (--)
Prev Close
€4.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
229,163
52-wk High
€5.78
52-wk Low
€2.87

Latest Key Developments (Source: Significant Developments)

MdxHealth Q1 revenue growth of 128%, or $19.4 million
Monday, 8 May 2017 01:01am EDT 

May 8 (Reuters) - MDXHEALTH SA ::Q1 SHARP REVENUE GROWTH OF 128%, OR $19.4 MILLION, COMPARED TO THE SAME PERIOD IN 2016.CASH AND CASH EQUIVALENTS ON APRIL 30 2017 OF $35.1 MILLION.THE COMPANY MAINTAINS ITS GUIDANCE FOR THE 2017 FISCAL YEAR.FOR 2017: GROWTH BETWEEN 55% TO 75% ON PRODUCT AND SERVICE INCOME.  Full Article

MDxHealth and Maastricht University collaborate on (EPI)genetic cancer diagnostics
Friday, 5 May 2017 01:00am EDT 

May 5 (Reuters) - MDxHealth SA ::Mdxhealth and maastricht university collaborate on next generation (EPI)genetic cancer diagnostics.Under the terms of the multi-year research and development agreement, the collaboration will focus on developing (EPI)genetic-based assays to provide better insight in the diagnosis, staging and treatment of cancer patients.  Full Article

Mdxhealth and Exact Sciences sign collaboration agreement
Thursday, 27 Apr 2017 01:00am EDT 

April 27 (Reuters) - Mdxhealth Sa : :Mdxhealth and Exact Sciences sign collaboration agreement for collaboration in the growing field of epigenetics and molecular diagnostics.These acquisitions include one-time fees totaling $15 million, including payments accrued since July 2016.Exact Sciences is also acquiring Mdxhealth patents directed toward colorectal cancer.  Full Article

Mdxhealth signs an exclusive licensing deal with Ghent University in Belgium
Tuesday, 4 Apr 2017 01:01am EDT 

Mdxhealth SA : Signed an exclusive licensing deal with Ghent University in Belgium . The collaboration agreements aim to develop cancer biomarker visualization technology .Has also joined forces with University to leverage licensed technology for company's current and future in vitro diagnostic (IVD) kits and laboratory developed tests (LDTs).  Full Article

MDxHealth signs agreement with Lab21 to make SelectMDX available in UK
Tuesday, 21 Mar 2017 02:01am EDT 

MDxHealth SA :Signs agreement with Lab21 to make SelectMDX liquid biopsy test available in the United Kingdom.  Full Article

MDxHealth: SelectMDx chosen by Michigan Medicine
Wednesday, 8 Mar 2017 01:00am EST 

MDxHealth SA :Reg-SelectMDx chosen by Michigan Medicine as pre-biopsy diagnostic tool in groundbreaking us prostate cancer risk clinic.  Full Article

Mdxhealth signs agreement for distribution of SelectMDx throughout Central-South Italy
Thursday, 23 Feb 2017 01:05am EST 

Mdxhealth SA :Signs distribution deal to make its selectMDx for prostate cancer test available to Istituto Diagnostico Varelli's urology clients throughout Central-South Italy.  Full Article

MDxHealth cash position at year end $30.9 mln
Thursday, 23 Feb 2017 01:00am EST 

MDxHealth SA : Reports FY revenue of $30 million, up 70 pct from 2015 . FY EBITDA loss of $11.1 million improved by $2.5 million from 2015 . Cash and cash equivalents of $30.9 million, at December 31, 2016 . Sees growth between 55-75 pct on product and service income, excluding royalties and milestone payments in 2017 .Maintaining focus on its strategic priorities during 2017.  Full Article

MDxHealth awarded ConfirmMDx testing contract by US VA
Wednesday, 8 Feb 2017 01:00am EST 

MDxHealth SA :MDxHealth awarded US department of Veterans Affairs (VA) contract for ConfirmMDx testing.  Full Article

MDxHealth expects to achieve upgraded guidance for FY 2016 and appoints new CFO
Monday, 9 Jan 2017 01:00am EST 

MDxHealth SA : MDxHealth announces preliminary update on 2016 results and appointment of CFO . Expects to achieve upgraded market guidance for FY 2016 financial results following continued strong growth of ConfirmMDx and early adoption of SelectMDx during year . Underlying earnings before interest, taxes, depreciation and amortization (ebidta) are also expected to improve compared to 2015 . Full-Year 2016 results will reflect initial sales of company's SelectMDx for prostate cancer "liquid biopsy" test . Co previously upgraded its expected full-year revenue growth to more than 60 percent compared with its initial guidance predicting growth of 30-50 percent over 2015 .MDxHealth announces appointment of Jean-Marc Roelandt as chief financial officer with effect from January 15, 2017.  Full Article

More From Around the Web

BRIEF-MdxHealth Q1 revenue growth of 128%, or $19.4 million

* Q1 SHARP REVENUE GROWTH OF 128%, OR $19.4 MILLION, COMPARED TO THE SAME PERIOD IN 2016